MAb NJ001 inhibits lung adenocarcinoma invasiveness by directly regulating TIMP-3 promoter activity via FOXP1 binding sites.

Chunrong GuYing LuoShichang ZhangJian XuJiexin ZhangHuanyu JuJingping LiuLixia ZhangYan ZhangLei WuErfu XieTing XuShiyang Pan

Published in: Thoracic cancer (2020)

MAb NJ001 inhibits invasiveness and metastasis in lung AD through the FOXP1 binding sites in the TIMP-3 promoter region. It may have clinical applications in preventing and treating metastatic lung AD.

Keyphrases

regulatory t cells
dna methylation
transcription factor
gene expression
monoclonal antibody
small cell lung cancer
squamous cell carcinoma
dendritic cells